Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)

BACKGROUND: Bromonitrozidine (RRx-001) is a minimally toxic, NLRP3 inhibitor that has been observed, in experimental systems, to also downregulate CD47, repolarize tumor associated macrophages (TAMs) and normalize aberrant tumor perfusion. This phase 1 pilot study was undertaken to determine the saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Reid, Tony, Oronsky, Bryan, Caroen, Scott, Quinn, Mary, Williams, Jeannie, Cabrales, Pedro, Abrouk, Nacer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028591/
https://www.ncbi.nlm.nih.gov/pubmed/36960054
http://dx.doi.org/10.3389/fimmu.2023.1104753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028591/
https://www.ncbi.nlm.nih.gov/pubmed/36960054
http://dx.doi.org/10.3389/fimmu.2023.1104753

Ejemplares similares